Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Piyush Verma, Lajpreet Kaur, Priyanka Aswal, Anju Singh, Himanshu Ojha, Afreen Jahan Rahman, Rahul Singhal, Anjani K. Tiwari & Mallika Pathak. (2023) Luminescence studies of binding affinity of vildagliptin with bovine serum albumin. Journal of Biomolecular Structure and Dynamics 41:7, pages 3002-3013.
Read now
Read now
Ashwani Sharma, Tarun Virmani, Anjali Sharma, Vaishnavi Chhabra, Girish Kumar, Kamla Pathak & Abdulsalam Alhalmi. (2022) Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity 15, pages 1845-1864.
Read now
Read now
Viswanathan Mohan, Abdul Zargar, Manoj Chawla, Ameya Joshi, Usha Ayyagari, Bipin Sethi, Kumar Gaurav, Usha Rani H Patted, Seema Vikas Bhagat & Amey Ishwara Mane. (2021) Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study. Diabetes, Metabolic Syndrome and Obesity 14, pages 2925-2933.
Read now
Read now
Gail Fernandes, Joana E. Matos, Dena H. Jaffe, Grace Beyer, Lingfeng Yang, Kristy Iglay, Ira Gantz & Swapnil Rajpathak. (2020) Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin. Current Medical Research and Opinion 36:3, pages 377-386.
Read now
Read now
Charles Saab, Feryal A Al-Saber, Jihad Haddad, Mahir Khalil Jallo, Habib Steitieh, Giovanni Bader & Mohamed Ibrahim. (2015) Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study. Vascular Health and Risk Management 11, pages 149-155.
Read now
Read now
Matthias Blüher, Anja Schweizer, Giovanni Bader & James E Foley. (2014) Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vascular Health and Risk Management 10, pages 661-664.
Read now
Read now
R. Göke, J. B. Gruenberger, G. Bader & M. Dworak. (2014) Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. Current Medical Research and Opinion 30:5, pages 785-789.
Read now
Read now
Ibrahim Gueler, Susanne Mueller, Matthias Helmschrott, Christian U Oeing, Christian Erbel, Lutz Frankenstein, Christian Gleißner, Arjang Ruhparwar, Philipp Ehlermann, Thomas J Dengler, Hugo A Katus & Andreas O Doesch. (2013) Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Design, Development and Therapy 7, pages 297-303.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Bernard Charbonnel, Anja Schweizer & Sylvie Dejager. (2013) Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?. Hospital Practice 41:2, pages 93-107.
Read now
Read now
Sylvie Dejager, Anja Schweizer & James E Foley. (2012) Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vascular Health and Risk Management 8, pages 339-348.
Read now
Read now
Asger Lund & Filip K. Knop. (2012) Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Current Medical Research and Opinion 28:5, pages 731-736.
Read now
Read now
Sylvie Dejager & Anja Schweizer. (2012) Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment. Hospital Practice 40:2, pages 7-21.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Mohamed Hassanein, Wasim Hanif, Waqar Malik, Ali Kamal, Parnia Geransar, Nicola Lister, Chris Andrews & Anthony Barnett. (2011) Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Current Medical Research and Opinion 27:7, pages 1367-1374.
Read now
Read now
Articles from other publishers (61)
Carme Grau-Bové, Carlos González-Quilen, Giulia Cantini, Patrizia Nardini, Beatriz Espina, Daniele Bani, Ximena Terra, MTeresa Blay, Esther Rodríguez-Gallego, Michaela Luconi, Anna Ardévol & Montserrat Pinent. (2022) GLP1 Exerts Paracrine Activity in the Intestinal Lumen of Human Colon. International Journal of Molecular Sciences 23:7, pages 3523.
Crossref
Crossref
Ilora Bandyopadhyay, Sunny Dave, Amita Rai, Madhavan Nampoothiri, Mallikarjuna Rao Chamallamudi & Nitesh Kumar. (2022) Oral Semaglutide in the Management of Type 2 DM: Clinical Status and
Comparative Analysis. Current Drug Targets 23:3, pages 311-327.
Crossref
Crossref
Sahar Hossam Elhini, Amal K. Hussien, Ahmed Abd Elsamie Omran, Asmaa A. Elsayed & Haitham saeed. (2021) Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clinical and Experimental Pharmacology and Physiology 48:12, pages 1589-1602.
Crossref
Crossref
Jessica Phillips, Jenny H. C. Chen, Esther Ooi, Janelle Prunster & Wai H. Lim. (2021) Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. Frontiers in Clinical Diabetes and Healthcare 2.
Crossref
Crossref
Vivek Bora & Bhoomika M. Patel. (2021) Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer. Life Sciences 274, pages 119329.
Crossref
Crossref
Anna Veelen, Edmundo Erazo-Tapia, Jan Oscarsson & Patrick Schrauwen. (2021) Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism 46, pages 101158.
Crossref
Crossref
Mohammed Altigani Abdalla, Harshal Deshmukh, Stephen Atkin & Thozhukat Sathyapalan. (2021) The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882198923.
Crossref
Crossref
Semra Ozdemir, Drishti Baid, Naina R. Verghese, Amanda YR. Lam, Phong Ching Lee, Adoree YY. Lim, Ling Zhu, Sonali Ganguly, Eric A. Finkelstein & Su-Yen Goh. (2020) Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. Value in Health 23:7, pages 842-850.
Crossref
Crossref
Ibrahim El Ebrashy, Nabil El Kafrawy, Rana Raouf & Diana Yousry. (2020) Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. Diabetes Research and Clinical Practice 162, pages 108042.
Crossref
Crossref
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp & Timo D. Müller. (2020) Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews 159, pages 34-53.
Crossref
Crossref
Noha H. Sayed, Nevine Fathy, Mona A. Kortam, Mostafa A. Rabie, Ahmed F. Mohamed & Ahmed S. Kamel. (2019) Vildagliptin Attenuates Huntington’s Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. Neurotherapeutics 17:1, pages 252-268.
Crossref
Crossref
James E. Foley. (2019) Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. Frontiers in Endocrinology 10.
Crossref
Crossref
Gamze Argun-Kurum, Fatma Kaya-Dagistanli & Melek Ozturk. (2019) DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats. Pharmacological Reports 71:4, pages 721-731.
Crossref
Crossref
Li Zang, Yin Han, Lixian Chen, Daqing Hu, Hui Jin, Nailong Yang, Xiaoyun Shi, Linlang Liang, Mingming Liu, Hong Fan, Quanmin Li & Yiming Mu. (2019) Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study. Diabetes Therapy 10:4, pages 1391-1405.
Crossref
Crossref
Arintaya Phrommintikul, Wanwarang Wongcharoen, Sirinart Kumfu, Thidarat Jaiwongkam, Siriluck Gunaparn, Siriporn Chattipakorn & Nipon Chattipakorn. (2019)
Effects of dapagliflozin
vs
vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study
. British Journal of Clinical Pharmacology 85:6, pages 1337-1347.
Crossref
Crossref
Camilla Kienast, Hanns-Christian Gunga & Mathias Steinach. (2019) Neuropeptide Y – Its role in human performance and extreme environments. REACH 14-15, pages 100032.
Crossref
Crossref
Mi Seon Seo, Hongliang Li, Jin Ryeol An, In Duk Jung, Won-Kyo Jung, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Il-Whan Choi & Won Sun Park. (2018) Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle. Cardiovascular Toxicology 19:3, pages 244-254.
Crossref
Crossref
Keerthanaa Bhavadasan, Ann Merry Davis & Bharathi Kolanthavel. (2019) Impact of Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control and Cardiovascular Safety with Adherence: An Overview. Dubai Diabetes and Endocrinology Journal 25:3-4, pages 90-99.
Crossref
Crossref
Simona Ferjan, Andrej Janez & Mojca Jensterle. (2018) Dpp4 Inhibitor Sitagliptin As A Potential Treatment Option In Metformin-Intolerant Obese Women With Polycystic Ovary Syndrome: A Pilot Randomized Study. Endocrine Practice 24:1, pages 69-77.
Crossref
Crossref
Prabhat Agrawal, Apoorv Jain, Saurabh Bansal & Abhishek Raj. (2018) Diffuse erythematous rash after teneligliptin therapy: A case report. Journal of Family Medicine and Primary Care 7:6, pages 1571.
Crossref
Crossref
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn & Seung-Hyun Ko. (2017) A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids in Health and Disease 16:1.
Crossref
Crossref
Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura & Tatsuya Atsumi. (2017) The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovascular Diabetology 16:1.
Crossref
Crossref
Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan & Jixin Zhong. (2017) The regulatory role of DPP4 in atherosclerotic disease. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Simona FerjanAndrej JanezMojca Jensterle. (2017) Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Metabolic Syndrome and Related Disorders 15:10, pages 515-520.
Crossref
Crossref
Laurentiu M. Pop & Ildiko Lingvay. (2017) The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. Current Diabetes Reports 17:12.
Crossref
Crossref
Gagik R. Galstyan, Ekaterina A. Shestakova & Igor A. Sklyanik. (2017) Obesity and type 2 diabetes: can we find a compromised treatment solution?. Diabetes mellitus 20:4, pages 270-278.
Crossref
Crossref
KM Prasanna Kumar, Sujoy Ghosh, William Canovatchel, Nishant Garodia & Sujith Rajashekar. (2017) A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism 21:1, pages 196.
Crossref
Crossref
Jong-Ha Baek, Bo Ra Kim, Jeong Woo Hong, Soo Kyoung Kim, Jung Hwa Jung, Jaehoon Jung & Jong Ryeal Hahm. (2016) Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up. Kosin Medical Journal 31:2, pages 146-156.
Crossref
Crossref
L.-N. Ji, C.-Y. Pan, J.-M. Lu, H. Li, D.-L. Zhu, Q. Li, Q.-F. Li, Y.-D. Peng, H.-M. Tian, C. Yao, Z.-G. Zhao, L. Wang & B.-H. Wang. (2016) Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diabetes, Obesity and Metabolism 18:8, pages 775-782.
Crossref
Crossref
Bo Ahrén & James E. Foley. (2016) Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59:5, pages 907-917.
Crossref
Crossref
Masato Odawara & Rieko Sagara. (2016) Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan. Journal of Diabetes & Metabolic Disorders 15:1.
Crossref
Crossref
Ahmed M. Mostafa, Nadia M. Hamdy, Hala O. El-Mesallamy & Sherif Z. Abdel-Rahman. (2015) Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes. Biochemical and Biophysical Research Communications 468:4, pages 900-905.
Crossref
Crossref
B. Ahrén. (2015) Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. Diabetes & Metabolism 41:6, pages 6S3-6S8.
Crossref
Crossref
TAKUMI ONOYAMA, MASAHIKO KODA, TOSHIAKI OKAMOTO, MANABU KISHINA, TOMOMITSU MATONO, TAKAAKI SUGIHARA & YOSHIKAZU MURAWAKI. (2015) Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice. Molecular Medicine Reports 12:5, pages 6895-6902.
Crossref
Crossref
A Ram Hong, Jeun Lee, Eu Jeong Ku, Yul Hwangbo, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang & Soo Lim. (2015) Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. Diabetes Research and Clinical Practice 109:1, pages 141-148.
Crossref
Crossref
S. Halimi, B. Charbonnel, P. Monguillon & S. Dejager. (2015) Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?. Médecine des Maladies Métaboliques 9:1, pages 53-63.
Crossref
Crossref
Viorica Ionut & Richard N. Bergman. 2015. The Clinician’s Guide to the Treatment of Obesity. The Clinician’s Guide to the Treatment of Obesity
1
18
.
Christoffer Clemmensen, Timo D. Müller, Brian Finan, Matthias H. Tschöp & Richard DiMarchi. 2016. Metabolic Control. Metabolic Control
437
459
.
Bo Ahrén, James Edward Foley, Sylvie Dejager, Mouna Akacha, Qing Shao, Guenter Heimann, Markus Dworak & Anja Schweizer. (2014) Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?. Diabetes Therapy 5:2, pages 459-469.
Crossref
Crossref
Gabriella A. Heruc, Michael Horowitz, Carolyn F. Deacon, Christine Feinle-Bisset, Christopher K. Rayner, Natalie Luscombe-Marsh & Tanya J. Little. (2014) Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American Journal of Physiology-Endocrinology and Metabolism 307:9, pages E830-E837.
Crossref
Crossref
Rüdiger Göke, Giovanni Bader & Markus Dworak. (2014) Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany. Diabetes Therapy 5:1, pages 183-191.
Crossref
Crossref
Masato Odawara, Izumi Hamada & Manabu Suzuki. (2014) Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 5:1, pages 169-181.
Crossref
Crossref
V. Lukashevich, S. Del Prato, M. Araga & W. Kothny. (2013) Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, Obesity and Metabolism 16:5, pages 403-409.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Ryo Kodera, Kenichi Shikata, Tetsuharu Takatsuka, Kaori Oda, Satoshi Miyamoto, Nobuo Kajitani, Daisho Hirota, Tetsuichiro Ono, Hitomi Kataoka Usui & Hirofumi Makino. (2014) Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochemical and Biophysical Research Communications 443:3, pages 828-833.
Crossref
Crossref
Anja Schweizer & Sylvie Dejager. (2013) Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment. Diabetes Therapy 4:2, pages 257-267.
Crossref
Crossref
Stefano Del Prato, Cristina Bianchi, Angela Dardano & Roberto Miccoli. (2013) Insulin as an Early Treatment for Type 2 Diabetes. Diabetes Care 36:Supplement_2, pages S198-S204.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref
Sang Ah Lee. (2013) DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. The Journal of Korean Diabetes 14:3, pages 128.
Crossref
Crossref
Hélène Gilet, Jean-Bernard Gruenberger, Giovanni Bader & Muriel Viala-Danten. (2012) Demonstrating the Burden of Hypoglycemia on Patients' Quality of Life in Diabetes Clinical Trials: Measurement Considerations for Hypoglycemia. Value in Health 15:8, pages 1036-1041.
Crossref
Crossref
Joana Rosmaninho-Salgado, Ana Patricia Marques, Marta Estrada, Magda Santana, Vera Cortez, Eric Grouzmann & Cláudia Cavadas. (2012) Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression. Peptides 37:1, pages 49-54.
Crossref
Crossref
C. Pan, X. Xing, P. Han, S. Zheng, J. Ma, J. Liu, X. Lv, J. Lu & G. Bader. (2012) Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 14:8, pages 737-744.
Crossref
Crossref
M.S. Fineman, B.B. Cirincione, D. Maggs & M. Diamant. (2012) GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 14:8, pages 675-688.
Crossref
Crossref
L. Cai, Y. Cai, Z. J. Lu, Y. Zhang & P. Liu. (2012) The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy and Therapeutics 37:4, pages 386-398.
Crossref
Crossref
Steven P. Vickers & Peter G. Clifton. (2012) Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology 63:1, pages 124-131.
Crossref
Crossref
Giuseppe DerosaPietro D. RagonesiAnna CarboneElena FogariLucio BianchiAldo BonaventuraDavide RomanoArrigo F.G. CiceroPamela Maffioli. (2012) Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients. Diabetes Technology & Therapeutics 14:6, pages 475-484.
Crossref
Crossref
Stefano Del PratoAntonio NicolucciAugusto C. Lovagnini-ScherSalvatore TurcoSergio LeottaGiacomo Vespasiani. (2012) Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine—the ELEONOR Study. Diabetes Technology & Therapeutics 14:2, pages 175-182.
Crossref
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Crossref
B. Ahrén, A. Schweizer, S. Dejager, E. B. Villhauer, B. E. Dunning & J. E. Foley. (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes, Obesity and Metabolism 13:9, pages 775-783.
Crossref
Crossref
A. Schweizer, S. Dejager, J. E. Foley, Q. Shao & W. Kothny. (2011) Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes, Obesity and Metabolism 13:1, pages 55-64.
Crossref
Crossref
David Heal, Jane Gosden & Sharon Smith. 2011. International Review of Neurobiology Volume 96. International Review of Neurobiology Volume 96
73
109
.